Compare Gap Inc (GAP) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Organon & Co. Common Stock — how do they compare? Gap Inc trades at $22.66 (market cap $8.02B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Gap Inc is far larger — about 2.2× Organon & Co. Common Stock's market cap, and Gap Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Organon & Co. Common Stock for 0 Days on average.
| GAP | OGN | |
|---|---|---|
Market Cap | $8.02B | $3.62B |
Volume | 4,496,595 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $13.81 |
52-Week Low | $18.35 | $5.70 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $11.25B | $11.04B |
Dividend Yield | 3.07% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $22.67, down 0.48% on the day, with a bullish technical signal supported by strong moving averages. The company shows improving fundamentals with revenue growth to $15.09B in 2025 and net income margin expanding to 8.14%. Recent strategic moves include music partnerships and board appointments, while analyst consensus targets $25.67 with 31% buy ratings.
The outlook remains positive with projected 2026 revenue of $15.3B and net income of $1.2B, though risks include Old Navy's sales decline and competitive pressures. Valuation appears attractive with P/E of 6.88 and P/S of 0.56, suggesting potential upside to consensus targets if execution continues.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
